Skip directly to content

XELJANZ® (tofacitinib citrate) Resource Center | Safety Info

Resource Center

XELJANZ® (tofacitinib citrate) has been studied in combination with nonbiologic DMARDs and as
monotherapy. XELJANZ was evaluated in a global clinical development program that included
6 randomized, controlled, double-blind studies. The results of these studies are summarized here, along
with a presentation on the mechanism of action of XELJANZ and a downloadable version of the
Prescribing Information.


Understanding Pharmacokinetic Equivalence

XELJANZ® XR (tofacitinib citrate) extended-release 11-mg tablet is indicated for the treatment of adults with moderate to severe rheumatoid arthritis. XELJANZ XR contains the same active ingredient as XELJANZ (tofacitinib citrate) 5mg tablets.
Click here to understand how the once-daily XELJANZ XR is pharmacokinetically equivalent to the twice-daily XELJANZ.


XELJANZ XR: A Once-daily Oral Treatment Option for Patients With Rheumatoid Arthritis

XELJANZ XR contains the same active ingredient as XELJANZ – tofacitinib. Learn more about the pivotal studies of the XELJANZ XR once-daily development program that demonstrated pharmacokinetic equivalence with twice-daily XELJANZ.

View presentation

Herpes Zoster

Herpes Zoster in Patients Receiving
Disease-modifying Antirheumatic Drugs

View presentation

Mechanism of Action

Tofacitinib, the active ingredient in
XELJANZ (tofacitinib citrate)/XELJANZ® XR (tofacitinib citrate) extended-release, is a small molecule inhibitor of JAK enzymes.
Discover how inhibiting the JAK pathways
reduces the cytokine signaling that drives
inflammation in rheumatoid arthritis. Learn
more about the mechanism of action

View presentation

Clinical Trials

Phase III Clinical Trials

Phase III clinical trial data

View presentation

More information regarding Pfizer trials for XELJANZ can be found at:

Go to website